Advanced Pharma CR, LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$2,157,166	118
2024	Research	$385,725	8
2023	Research	$2,282,026	4
2022	Research	$24,318	8
2021	Research	$1,498,362	102
2020	Research	$603,034	76
2019	Research	$28,878	16

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $3,157,410 9 payments
Merck Sharp & Dohme Corporation $2,253,643 6 payments
Gilead Sciences, Inc. $1,451,801 194 payments
Incyte Corporation $96,311 118 payments
Amgen Inc. $20,343 5 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Open-Label, Parallel-Group, Single-dose, Relative Bioavailability Study of the Pharmacokinetics of Subcutaneous Abatacept (BMS-188667) Drug Product Converted from Drug Substance of a New Abatacept Drug Substance Process J Relative to the Current Abatacept Drug Process F in Healthy Participants $2,092,691 1 payment
A Phase 1 Clinical Study in Healthy Females of Nonchildbearing Potential to Compare the Pharmacokinetics of Sotatercept MK-7962 Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation $1,630,579 1 payment
A Randomized, Open-Label, Parallel-Group, Single-dose, Relative Bioavailability Study of the Pharmacokinetics of Subcutaneous Abatacept (BMS-188667) Drug Product Converted from Drug Substance of a New Abatacept Drug Substance Process J Relative to the Current Abatacept Drug Process F in Healthy Participants $512,590 1 payment
A Phase 1 Clinical Study in Healthy Females of Nonchildbearing Potential to Compare the Pharmacokinetics of Sotatercept MK-7962 Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation $420,119 1 payment
A Randomized, Open-Label, Parallel-Group, Single-dose, Relative Bioavailability Study of the Pharmacokinetics of Subcutaneous Abatacept (BMS-188667) Drug Product Converted from Drug Substance of a New Abatacept Drug Substance Process J Relative to th $373,072 3 payments
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Molnupiravir MK-4482 MOV in Participants with Severe Renal Impairment. $182,735 2 payments
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease $163,987 2 payments
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of Remdesivir and Metabolites in Participants with Normal Renal Function and Renal Impairment $131,799 1 payment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of Remdesivir and Metabolites in Participants with Normal Renal Function and Renal Impairment $98,435 1 payment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of Remdesivir and Metabolites in Participants with Normal Renal Function and Renal Impairment $86,808 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.